A Comparative Clinical Study to Assess Pain Score and Wound Healing Following Fractional Ablation With a DFG Laser and CO2 Laser
Massachusetts General Hospital · NCT06295471
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 23
- US sites recruiting
- 1
- Study start
- October 16, 2024
- Record last updated
- April 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This research study aims assess whether the Difference Frequency Generation (DFG) laser could be a better alternative to the CO2 laser in terms of reduced side effects and patient downtime.
Being studied: DFG Laser; CO2 Laser; Optical coherence tomography (OCT)
Conditions: Healthy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subjects must be able and willing to provide written informed consent and comply with the requirements of the study protocol;
- Subjects must be in good general health, based on answers provided during the screening visit;
- Subjects must be able to read and understand English.
- Subjects must be above the age of 18.
- Subjects must have no history of skin conditions that affect the integrity of the skin barrier.
Exclusion Criteria
- Are pregnant or lactating;
- Have a history of drug or alcohol abuse or have reported habitual alcohol intake greater than 2 standard drinks per day [e.g., 2 beers, 2 glasses of wine, or 2 mixed drinks];
- Are smoking or have a history of smoking;
- Presence of eczema, psoriasis, skin wounds or ulcers, or any other skin disease on the thighs;
- Have birth marks, tattoos, scars, or any other disfiguration of the skin in the skin area of interest;
- Presence of sunburn or tan in the treatment area;
- Use of any topical application of retinoids in the area of interest or systemic retinoids in the past 6 months;
- Use of any prescription topical medication, such as corticosteroids or hydroquinone on the skin area of interest in the past 6 months;
- History of blood-clotting abnormality;
- History of keloid formation or hypertrophic scarring;
- History of allergic reaction to local anesthesia, aluminum chloride, and/or glycerol;
- Investigator, interfere with study evaluations or pose a risk to subject safety during the study;
- Exhibits any clinical conditions or takes any medication which in the opinion of the investigator may interfere with the study or pose a risk to subject safety during the study;
- Is not able to follow study protocol.
Recruiting US locations
MGH Clinical Unit for Research Trials & Outcomes in Skin
Boston, MA 02114
Site contact: Alicia Van Cott, NP · 617-726-4454 · mansteinlab@mgh.harvard.edu
Study contacts (from the official record)
- Alicia Van Cott, NP · 617-726-4454 · mansteinlab@mgh.harvard.edu
- Amelia Carlson, BS · 617-726-4454 · mansteinlab@mgh.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+